Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It is employed to improve cardiac contractility in patients with acute decompensated heart failure. By enhancing the sensitivity of cardiac troponin C to calcium, it increases stroke volume without raising intracellular calcium levels, providing hemodynamic support in severe heart failure. The drug also induces peripheral vasodilation through opening of ATP‑sensitive potassium channels, aiding in the reduction of cardiac afterload.

GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure conditions where enhanced cardiac contractility is required.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Chronic heart failure with reduced ejection fraction (as adjunct therapy): augments contractility when standard treatments are insufficient.

Levosimendan may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Hypotension: mild to moderate drop in blood pressure. - Headache: transient cranial discomfort. - Nausea: occasional gastrointestinal upset. - Dizziness: feeling of light‑headedness during infusion.

Serious or Rare Side Effects: - Arrhythmias: ventricular or atrial rhythm disturbances. - Severe hypotension: profound blood pressure fall requiring intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Tachycardia: rapid heart rate that may be symptomatic. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes indicating liver stress.

Levosimendan requires careful clinical monitoring and patient selection. - Hemodynamic monitoring: continuously observe blood pressure and heart rate during infusion. - Renal impairment: adjust infusion rate and monitor renal function closely. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant vasodilators: avoid excessive hypotension by adjusting doses. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect causing severe hypotension. - Beta‑blockers: may blunt the desired inotropic response. - Calcium channel blockers: potential for excessive hypotension. - Other inotropes (e.g., dobutamine): risk of synergistic cardiac stress. - Phosphodiesterase inhibitors: increased risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotension; monitor volume status. - ACE inhibitors/ARBs: additive blood‑pressure lowering; observe hemodynamics. - Anticoagulants: monitor for bleeding if hypotension occurs. - Antidepressants (SSRIs): watch for rare serotonin‑related effects when combined with other serotonergic agents.